Ascendis Pharma reports oncology as second independent area of focus

Ascendis Pharma introduced Vision 3×3, the company’s strategic roadmap through 2025 to achieve sustainable growth, at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco. As part of that vision, the company also announced oncology as its second independent therapeutic area of focus. The goal of Ascendis Pharma’s Vision 3×3 strategic roadmap through 2025 is to achieve sustainable growth through multiple approaches: Obtain regulatory approval for three endocrinology rare disease products: TransCon hGH for pediatric growth hormone deficiency, TransCon PTH for adult hypoparathyroidism (HP), and TransCon CNP for achondroplasia. Create further growth of the company’s endocrinology rare disease pipeline through: Label expansion programs with the goal of obtaining 9 indications in total; and Global clinical reach either directly or through partnerships. Build an integrated commercial business for the endocrinology rare disease franchise in North America and select European countries, and establish a global commercial presence with partners in other geographic areas. Create three independent therapeutic areas, each with a diversified pipeline built on TransCon technologies and the company’s unique algorithm for product innovation. The company has established oncology as the next independent therapeutic area. Ascendis also announced that it has established oncology as its second independent therapeutic area. To lead the oncology research and development programs, Ascendis recently appointed Juha Punnonen, MD, PhD, as Senior Vice President and Head of Oncology.
https://thefly.com/landingPageNews.php?id=2844671